A micropatterned hepatocyte coculture model for assessment of liver toxicity using high-content imaging analysis

Assay and Drug Development Technologies

Volumn 12, Issue 1, 2014, Pages 16-27

  Trask, O Joseph ^a   Moore, Amanda ^b   Lecluyse, Edward L ^a  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^b Hepregen Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; DICLOFENAC; IBUPROFEN; ROTENONE; VALINOMYCIN;

APOPTOSIS; ARTICLE; CELL COMPONENT; CELL LEVEL; CELL MEMBRANE PERMEABILITY; CELL SHAPE; CELL SIZE; CELL STRAIN HEPG2; CELL SUBPOPULATION; CELL SURVIVAL; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; CYTOARCHITECTURE; EX VIVO STUDY; FIBROBLAST; HEPATOCYTE ISLAND; HIGH CONTENT SCREENING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; LIVER CELL CULTURE; LIVER MITOCHONDRION; LIVER TOXICITY; METABOLIC CAPACITY; MICROPATTERNED HEPATOCYTE COCULTURE; MICROTITER PLATE ASSAY; MORPHOMETRICS; PLURIPOTENT STEM CELL; PRIMARY CELL CULTURE; SCREENING;

APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG-INDUCED LIVER INJURY; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; FIBROBLASTS; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INSECTICIDES; MICROSCOPY, FLUORESCENCE; ROTENONE;

EID: 84896715122     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2013.525     Document Type: Article

References (33)

1. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-715.
2. LeCluyse EL, Witek RP, Andersen ME, Powers MJ: Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 2012;42:501-548.
3. Deleve LD, Wang X, Kaplowitz N, Shulman HM, Bart JA, Van Der Hoek A: Sinusoidal endothelial cells as a target for acetaminophen toxicity. Direct action versus requirement for hepatocyte activation in different mouse strains. Biochem Pharmacol 1997;53:1339-1345.
4. Kmiec Z: Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol 2001;161, III-XIII, 1-151.
5. Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD: Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 2004;32:359-363.
6. Moreau A, Maurel P, Vilarem MJ, Pascussi JM: Constitutive androstane receptor-vitamin D receptor crosstalk: consequence on CYP24 gene expression. Biochem Biophys Res Commun 2007;360:76-82.
7. Pascussi JM, Robert A, Nguyen M, et al.: Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005;115:177-186.
8. Roberts RA, Ganey PE, Ju C, Kamendulis LM, Rusyn I, Klaunig JE: Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci 2007;96:2-15.
9. Khetani SR, Bhatia SN: Microscale culture of human liver cells for drug development. Nat Biotechnol 2008;26:120-126.
10. Bhatia SN, Balis UJ, Yarmush ML, Toner M: Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. FASEB J 1999;13:1883-1900.
11. Wang WW, Khetani SR, Krzyzewski S, et al.: Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab Dispos 2010;38: 1900-1905.
12. Ukairo O, Kanchagar C, Moore A, et al.: Long-term stability of primary rat hepatocytes in micropatterned cocultures. J Biochem Mol Toxicol 2013;27: 204-212.
13. Rheinwald JG, Green H: Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975;6:331-343.
14. Abcam: Anti-cytochrome C antibody [2B5.F8] (ab115266). Available at: www.abcam.com/cytochrome-c-antibody-2b5-f8-ab115266.html (last accessed November 6, 2013).
15. Enzo Life Sciences: Cytochrome c, mAb (2B5.F8). Available at: www.enzolife sciences.com/ADI-905-631/cytochrome-c-mab-2b5.f8 (last accessed November 6, 2013).
16. Novus Biologicals: Cytochrome C Antibody (2B5.F8) (NBP1-19186). Available at: www.novusbio.com/Cytochrome-C-Antibody-2B5F8-NBP1-19186.html (last accessed November 6, 2013).
17. Liu X, Kim CN, Yang J, et al.: Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147-157
18. D'Herde K., De Prest B., Mussche S., et al.: Ultrastructural localization of cytochrome c in apoptosis demonstrates mitochondrial heterogeneity. Cell Death Differ 2000;7:331-337.
19. Tafani M, Karpinich NO, Hurster KA, et al.: Cytochrome c release upon Fas receptor activation depends on translocation of full-length bid and the induction of the mitochondrial permeability transition. J Biol Chem 2002;277:10073-10082.
20. Li P, Nijhawan D, Budihardjo I, et al.: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-489.
21. Towne D, Nicholl E, Comess K, et al.: Development of a high-content screening assay panel to accelerate mechanism of action studies for oncology research. J Biomol Screen 2012;17:1005-1017.
22. Poplineau M, Doliwa C, Schnekenburger M, et al.: Epigenetically induced changes in nuclear textural patterns and gelatinase expression in human fibrosarcoma cells. Cell Prolif 2013;46:127-136.
23. Trask OJ Jr: Nuclear factor kappa B (NF-kB) translocation assay development and validation for high content screening. In: Assay Guidance Manual [Internet]. Sittampalam GS, Gal-Edd N, Arkin M, et al. (eds.). Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MD, 2004.
24. Buchser W, Collins M, Garyantes T, et al.: Assay development guidelines for image-based high content screening, high content analysis and high content imaging. In: Assay Guidance Manual [Internet]. Sittampalam GS, Gal-Edd N, Arkin M, et al. (eds.). Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MD, 2004.
25. Zanella F, Lorens J, Link W: High content screening: seeing is believing, Trends Biotechnol 2010;28:237-245.
26. Trask OJ, Nickischer D, Baker A, et al.: High-throughput automated confocal microscopy imaging screen of a kinase-focused library to identify p38 mitogen-activated protein kinase inhibitors using the GE InCell 3000 analyzer. Methods Mol Biol 2009;565:159-186.
27. Vogt A, Lazo J: Discovery of protein kinase phosphatase inhibitors. High content screening: a powerful approach to systems cell biology and drug discovery. Methods Mol Biol 2007;356:389-399.
28. Trask OJ, Baker A, Williams RG, et al.: Assay development and case history of a 32K biased library high content MK2-EGFP translocation screen to identify p38 mitogen activated protein kinase inhibitors. Measuring biological responses with automated microscopy. Methods Enzymol 2006;414:419-439.
29. Carpenter A, Jones T, Lamprecht M, et al.: CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 2006;7:R100.
30. Green D, Reed J: Mitochondria and apoptosis. Science 1998;281:1309-1312.
31. Earnshaw WC: Nuclear changes in apoptosis. Curr Opin Cell Biol 1995;7: 337-343.
32. Shariff A, Kangas J, Coelho L, et al.: Automated image analysis for high-content screening and analysis. J Biomol Screen 2010;15:726-734.
33. Hill A, Lapan P, Li Y, et al.: Analysis of multiparamteric HCS data. In: High Content Screening: Science, Techniques, and Applications. Haney SA (ed), pp. 329-354. Wiley Interscience, Hoboken, NJ, 2008.